Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TENX
Strong SellSinkerTenax Therapeutics, Inc. · Healthcare · United States · $80M · Avg Vol: $18M/d
12
StockRankGet insider-trade alerts
Q
33
V
35
M
20
P/E (TTM)
—
ROE
-59.8%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | — | -0.65 | -0.35 | -0.15 | -0.47 | — | -1.48 | -1.45 | -1.50 | — |
| Shares | — | 26.5M | 26.5M | 26.5M | 26.5M | 0.0% | — | — | — | — |
| Debt | 0.3M | 0.8M | 0.5M | — | — | 31.3% | — | — | — | — |
| Equity | — | 1.5M | 8.1M | 92.0M | 97.1M | 302.1% | — | — | — | — |
| Op CF | — | -11.4M | -5.9M | -14.8M | -35.8M | — | -46.0M | — | — | — |
| Inv CF | 0.5M | -2.3K | 3.0K | 0 | — | — | — | — | — | — |
| Fin CF | — | 7.9M | 13.6M | 99.9M | 38.5M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-87.1%
SMA 50SMA 200
Close
$1.95
RSI (14)
54.5
52W High
$19.40
From 52W High
0.1%
SCORE BREAKDOWN
Quality
33
ROIC
-60.5%12.5
ROE
-59.8%15.8
GP/Assets
—N/A
Op. Margin
0.0%38.1
FCF/Assets
-18.0%22.5
Piotroski
211.9
Int. Cover
—N/A
D/E Ratio
0.00x98.1
Current Ratio
15.07x93.0
Value
35
P/E (TTM)
—N/A
EV/EBITDA
—N/A
P/FCF
—N/A
P/B
0.8x89.8
P/S
—N/A
Div Yield
—N/A
Momentum
20
52W High %
10%1.2
RS 6M
-99%0.4
SMA 50/200
0.77x13.4
EPS Rev 4W
+9.7%88.8
EPS Rev 12W
—N/A
EPS Improve
-1%22.1
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$80M
P/E (Forward)
-1.3x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TENX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TENX | Tenax Therapeutics, Inc.(you) | $80M | 12 | Strong Sell |
| MAIA | MAIA Biotechnology, Inc. | $81M | 11 | Strong Sell |
| ANVS | Annovis Bio, Inc. | $73M | 12 | Strong Sell |
| TELO | Telomir Pharmaceuticals, Inc. | $78M | 13 | Strong Sell |
| PLRX | Pliant Therapeutics, Inc. | $69M | 12 | Strong Sell |
| DWTX | Dogwood Therapeutics, Inc. | $90M | 9 | Strong Sell |
| OSTX | OS Therapies Incorporated | $76M | 15 | Strong Sell |
| GANX | Gain Therapeutics, Inc. | $77M | 7 | Strong Sell |
| CGTX | Cognition Therapeutics, Inc. | $97M | 13 | Strong Sell |
| CING | Cingulate Inc. | $77M | 6 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%